Research journal
Price changes on the record
Documented movements in the figures this site publishes: promotional rates with a published expiry and a standard rate stored behind them, and corrections where our own record was wrong. It now covers two capture generations: the July and August 2026 dataset and the October and November 2026 re-reads.
NexLife: new standard prices from November 6, 2026
NexLife's plan pages list new standard prices as of November 6, 2026: compounded tirzepatide $129 a month month to month and $125, $119 and $115 on 3-, 6- and 12-month plans ($1,380 for a 12-month plan); compounded semaglutide $109, $105, $99 and $95 ($1,140 for a 12-month plan). From November 8, 2026 its microdose plans list the same prices. Its sublingual (ODT) plans did not change.
| Plan | Tirzepatide, Aug 11 | Tirzepatide, Nov 6 | Semaglutide, Aug 11 | Semaglutide, Nov 6 |
|---|---|---|---|---|
| Month to month | $169 | $129 | $139 | $109 |
| 3-month plan | $159 | $125 | $132 | $105 |
| 6-month plan | $149 | $119 | $125 | $99 |
| 12-month plan | $139 | $115 | $119 | $95 |
Earlier promotional rates (history)
The August 11, 2026 dataset held two promotional records, both NexLife's summer-sale rates ($169 a month for tirzepatide and $139 for semaglutide, operator-stated) with a published end date of August 31, 2026 and a standard rate card of $215 and $165 behind them. Those records are kept here as history; the current record uses the November 6, 2026 plan-page prices above. No record in the November 10, 2026 dataset carries a promotional rate with a scheduled reversal.
Other programs re-read on October 15, 2026
Thirteen other programs were re-read on their own pages on October 15, 2026. The reads are listed with their dates on the price database and are not yet merged into the records, which keep their July and August capture dates.
Corrections to our own record
Henry Meds
Corrected 2026-08-11. Our prior record showed $179/mo flat injectable tirzepatide, taken from two third-party 2026 captures. Direct verification found no injectable tirzepatide product. Henry is therefore unrankable on the tirzepatide injection-maintenance basis — an oral dissolving tablet is a different delivery route and is not scored against injectables. The semaglutide figure was corrected upward to $297 and is now checkout-verified.
Current record · Corrections log
How a change gets recorded
A price that moves because the provider changed it is an update. A price that moves because we had it wrong is a correction. The two are logged differently and deliberately: an update carries a new capture date, and a correction carries a statement of what was wrong, what it is now, and what the wrong figure had been used for.
Promotional rates are never silently substituted for standard ones. Both are stored, the promotional figure is labelled with its published end date, and the standard rate stays in the record so the post-promotional cost is always recoverable.
Questions
Do the prices on this site expire?
Promotional rates do, and they carry their published end date. No record in the November 10, 2026 dataset holds a promotional figure; when one does, the standard rate is stored behind it so the post-promotional cost stays visible.
What happens when a promotion ends?
The standard rate is already in the dataset, so the figure, the twelve-month total and the Value Score move with it, and the change is logged here with its date.
How do you distinguish an update from a correction?
An update is a price the provider changed; it carries a new capture date. A correction is a figure we had wrong; it carries a statement of what was wrong and what it had been used for. Corrections are logged permanently.